



Larry Hogan, Governor · Boyd K. Rutherford, Lt. Governor · Robert R. Neall, Secretary

MARYLAND MEDICAL ASSISTANCE PROGRAM

Hospital Transmittal No. 272

MCO Transmittal No. 136

Pharmacy Transmittal No. 209

Physician Transmittal No. 147

January 09, 2020

TO: Hospitals
 Managed Care Organizations (MCOs)
 Pharmacies
 Physicians
 Neurologists

FROM: Jill Spector, Director *Jill Spector*
 Medical Benefits Management

RE: Carve Out and Preauthorization of Zolgensma®

Note: Please ensure that appropriate staff members in your organization are informed of the contents of this transmittal.

For dates of service on or after January 1, 2020, Maryland Medicaid will cover the drug Zolgensma® when treatment is determined to be medically necessary for spinal muscular atrophy.

The Medicaid Program will cover Zolgensma® via Fee-for-Service (FFS), not under the HealthChoice Managed Care benefit. Medical services related to the administration of this medication are the responsibility of the MCO. MCOs may require providers to obtain a preauthorization for medical services.

Preauthorizations

Providers must obtain a preauthorization for Zolgensma® from the Maryland Department of Health (MDH).

If Zolgensma® is purchased by and administered in a physician's office, the rendering physician must follow the preauthorization process in place with the Professional Services Program. The clinical criteria and the Preauthorization Request Form (Physician Administered Injectable

Drugs) are available at <https://mmcp.health.maryland.gov/pages/preauthorization-information.aspx>.

If Zolgensma® is purchased and dispensed through a pharmacy, the clinical criteria can be found at <https://mmcp.health.maryland.gov/pap/pages/Clinical-Criteria.aspx>, and the High Cost Drug Preauthorization Form is available at <https://mmcp.health.maryland.gov/pap/pages/Pharmacy-Program-Forms.aspx>.

Billing Instructions

In order for MDH to pay for Zolgensma®, the drug manufacturer must participate in the Medicaid Drug Rebate Program. Please make sure the J-Code/National Drug Code (NDC) is rebatable by going to the NDC Unit of Measure Listing on the Maryland Medical Program's Web Services site at <http://encrypt.emdhealthchoice.org/emedicaid/>.

Physicians

Until Zolgensma® receives a permanent J-Code, it will be reimbursed using the HCPCS code of J3490 with the modifier U4. Providers must also report a valid 11-digit NDC number and the quantity administered on the CMS-1500 claim form.

All claims following the Preauthorization Request Form for Physician Administered Injectable Drugs must be faxed to 410-767-6034. Electronic claims will NOT be accepted. If Zolgensma® is billed on a UB04 claim, facilities are responsible for ensuring that a preauthorization is obtained. Any claim without a preauthorization is subject to recoupment.

Pharmacies

Prescribers must complete the medication preauthorization process for Zolgensma®. Once the prior authorization has been issued, pharmacies may process the medication claim. MDH will reimburse the pharmacy for the medication if all criteria for coverage are met.

Questions

For questions related to preauthorizations through the Pharmacy Program, please call the Pharmacy Hotline at 1-800-492-5231, option 3.

For questions related to preauthorizations through the Professional Services Program, please call Kim Stevenson at 410-767-5706 or email kim.stevenson@maryland.gov